Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: Metabolism and function

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 363-376

  Schmid, H H O ^a   Berdyshev, E V ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANANDAMIDE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; ETHANOLAMINE DERIVATIVE; FATTY ACID DERIVATIVE; OLEIC ACID; PHOSPHOLIPID; CANNABINOID; DRUG RECEPTOR; ENDOCANNABINOID; FATTY ACID; ICOSANOID; N ACYLETHANOLAMINES; N-ACYLETHANOLAMINES;

CATABOLISM; METABOLISM; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL;

VERTEBRATA;

AMIDES; ANIMALS; CANNABINOIDS; EICOSANOIDS; ENDOCANNABINOIDS; ETHANOLAMINES; FATTY ACIDS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0036019421     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0348     Document Type: Article

References (142)

1. N-acylated glycerophospholipids and their derivatives
2. Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: Biochemistry and possible physiopathological relevance
3. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid arrudes
4. The role of sphingolipids in the process of signal transduction
5. Occurrence of N-acylethanolamine phospholipids in fish brain and spinal cord
6. Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus
7. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry
8. A new class of phosphatides isolated from soft wheat flour
9. N-acylphosphatidylethanolamine, a phospholipid that is rapidly metabolized during the early germination of pea seeds
10. Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: Signal transduction and membrane protection
11. Novel lipids of Butyrivibrio spp.
12. Identification of N-acylethanolamine phosphoglycerides and acylphosphatidylglycerol as the phospholipids which disappear as Dictyostelium discoideum cells aggregate
13. Pathways and mechanisms of N-acylethanolamine biosynthesis: Can anandamide be generated selectively?
14. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamide, an endogenous cannabinoid receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine
15. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidyl-ethanolamine, in rat brain
16. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain
17. Isotope dilution mass spectrometric measurements indicate that arachidonoylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue
18. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation
19. Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation
20. N-acylethanolamine accumulation in infarcted myocardium
21. Accumulation of N-acylethanolamine glycerophospholipids in infarcted myocardium
22. N-acylethanolamine phospholipid metabolism in normal and ischemic rat brain
23. 31P study
24. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration
25. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis
26. Phosphatidyl-(N-acyl)-ethanolamine. A lipid component of mammalian epidermis
27. Glycerophospho-(N-acyl)-ethanolamine lipids in degenerating BHK cells
28. Changes in lipid composition of neuroblastoma C 1300 N18 cell during differentiation
29. Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture
30. Endocannabinoids control spasticity in a multiple sclerosis model
31. Vanadate-induced activation of activator protein-1: Role of reactive oxygen species
32. 2-terminal kinase-dependent, p53-independent pathway
33. Translocation of protein kinase Cepsilon and protein kinase Cdelta to membrane is required for ultraviolet B-induced activation of mitogen-activated protein kinases and apoptosis
34. + cells
35. N-acylation of ethanolamine phospholipids in canine myocardium
36. N-acylation of dog heart ethanolamine phospholipids by transacylase activity
37. Properties of canine myocardial phosphatidylethanolamine N-acyltransferase
38. The role of cardiolipin as an acyl donor in N-acylethanolamine phospholipid biosynthesis
39. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type
40. Biosynthesis of N-acylethanolamine phospholipids by dog brain preparations
41. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
42. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
43. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells
44. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP
45. Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes
46. 2+-dependent transacylase and phosphodiesterase activities
47. 31PNMR and enzyme activity study
48. Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons
49. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system
50. Biosynthesis and turnover of anandamide and other N-acylethanolamines in peritoneal macrophages
51. N-acylation of dog heart ethanolamine phospholipids by acyl transfer does not involve hydrolysis
52. Alternative pathways of anandamide biosynthesis in rat testes
53. Catabolism of N-acylethanolamine phospholipids by dog brain preparations
54. N-acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate
55. Marked activation of the N-acylethanolamine-hydrolyzing phosphodiesterase by divalent cations
56. Properties of rat liver N-acylethanolamine amidohydrolase
57. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
58. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization
59. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain
60. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide
61. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
62. Molecular characterization of human and mouse fatty acid amide hydrolases
63. Anandamide amidohydrolase of porcine brain: cDNA cloning, functional expression and site-directed mutagenesis
64. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance
65. Receptor-dependent formation of endogenous cannabinoids in cortical neurons
66. The identification of N-2(hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent
67. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine
68. A proposed autocoid mechanism controlling mastocyte behavior
69. N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation
70. 9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells
71. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice
72. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
73. Characterization of cannabinoid receptors in the spleen and in mast cells
74. Pharmacology of cannabinoid receptor ligands
75. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the CB2 receptor. Comparison of the agonist activities of various cannabinoid receptor ligands in HL-60 cells
76. Phase behavior of synthetic N-acylethanolamine phospholipids
77. Incorporation of N-acylethanolamine phospholipids into egg phosphatidylcholine vesicles: Characterization and permeability properties of the binary systems
78. N-palmitoylphosphatidylethanolamine stabilizes liposomes in the presence of human serum: Effect of lipidic composition and system characterization
79. N-acylethanolamines as membrane topological stress compromising agents
80. 2+ release from mitochondria by N-acylethanolamines, a class of lipids synthesized in ischemic heart tissue
81. Effects of long-chain N-acylethanolamines on lipid peroxidation in cardiac mitochondria
82. Long-chain N-acylethanolamines inhibit lipid peroxidation in rat liver mitochondria under acute hypoxic hypoxia
83. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons
84. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
85. Anandamide may mediate sleep induction
86. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoylglycerol cannabinoid activity
87. Control of pain initiation by endogenous cannabinoids
88. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide
89. Anticonvulsant activity of N-palmitylethanolamide, a putative endocannabinoid, in mice
90. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs
91. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
92. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
93. Cannabinoid receptor-independent cell signaling by N-acylethanolamines
94. Structural deteminants for recognition and translocation by the anandamide transporter
95. Structure-activity relationships among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter
96. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes
97. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase
98. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
99. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells
100. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells
101. Ceramidase and ceramide synthesis in human kidney and cerebellu. Description of a new alkaline ceramidase
102. Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway
103. Anti-immunoglobulin-induced apoptosis in WEHI 231 cells revolves the slow formation of ceramide from sphingomyelin and is blocked by bcl-XL
104. The role of N-acylethanolamines in cell signalling
105. Identification of fatty acid amides in human plasma
106. Chemical characterization of a family of brain lipids that induce sleep
107. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells
108. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'
109. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase
110. Enzymatic synthesis of oleamide (cis-9, 10-octadeceneamide), an endogenous sleep-inducing lipid, by rat brain microsomes
111. Identification in pituitary tissue of a peptide-amidation activity that acts on glycine-extended peptides and requires molecular oxygen, copper, and ascorbic acid
112. Peptide substrate specificity of the alpha-amidating enzyme isolated from rat medullary thyroid CA-77 cells
113. Fatty acid amide biosynthesis: A possible new role for peptidylglycine α-amidating enzyme and acyl-coenzyme A:glycine N-acyltransferase
114. Characterization of a peptide alpha-amidation activity in human plasma and tissues
115. Alzheimer's disease: Low levels of peptide alpha-amidation activity in brain and CSF
116. Glycine N-acylase: Purification and properties
117. Identification of separate acyl-CoA:glycine and acyl-CoA:L-glutamine N-acyltransferase activities in mitochondrial fractions from liver of rhesus monkey and man
118. Characterization of the hypnotic properties of oleamide
119. The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist
120. Studies on the sedative and hypnotic effects of oleamide in mice
121. Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems
122. cis-9,10-octadecenoamide, an endogenous sleep-inducing CNS compound, inhibits lymphocyte proliferation
123. Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide
124. Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide
125. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells - Implications for cell proliferation and differentiation
126. + channels in vitro: A putative endogenous ligand for depressant drug sites in CNS
127. A receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA)
128. Brain lipids that induce sleep are novel modulators of 5-hydroxytrypamine receptors
129. Oleamide-induced modulation of 5-hydroxytryptamine receptor-mediated signaling
130. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide
131. 2 receptor mediated behavior in the rat by oleamide and the role of cannabinoid receptors
132. Serotonin receptors and their function in sleep, anxiety disorders and depression
133. 7) implicated in the regulation of mammalian circadian rhythms
134. GABA in the mammalian suprachiasmatic nucleus and its role in diurnal rhythmicity
135. Effective reduction of neuronal death by inhibiting gap junctional intercellular communication in a rodent model of global transient cerebral ischemia
136. Gap-junctional communication is required for the maturation process of osteoblastic cells in culture
137. Inhibition of gap-junctional communication induces the trans-differentiation of osteoblasts to an adipocytic phenotype in vitro
138. The sleep-inducing lipid oleamide deconvolutes gap junction communication and calcium wave transmission in glial cells
139. Gap junctions modulate survival-promoting effects of fibroblast growth factor-2 on cultured midbrain dopaminergic neurons
140. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
141. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
142. 2 receptor